

In re: Nicolette
USSN: 10/041,977
Filed: January 9, 2002
Page 2

Currently, claims 1, 4-5, 9-12, 19 24-28 are generic. Applicant is requested to elect a single species for each (a-h) of the following:

- a) One single species of cytotoxic T cells;
- b) a single species of solid phase support;
- c) a single species of structural motif and the corresponding SEQ ID NO;
- d) a single species of coding molecule;
- e) a single species of antigen presentation means;
- f) a single species of method of detecting T cell activation;*
- g) a singles species of releasable linker cleaving conditions or agent (*i.e.*, claim 7);
- h) a single species of method of detecting T cell activation.*

*It is noted that the recitation of species in both group "f" and group "h" is identical, *i.e.*, "a single species of method of detecting T cell activation". It is not clear to Applicant whether the aforementioned duplication is an error. In order to be fully responsive to the instant Office Action, clarification of the intended representative species of both group "f" and of group "h" is respectfully requested.

Pending Applicant's receipt of such clarification, the election submitted herewith is responsive to the species recited in groups "a" through "g" of the December 16, 2003 Restriction Requirement.

Applicant's undersigned attorney hereby elects with traverse to prosecute the following species for each of groups a through g:

- a) polyclonal T cells isolated from a site of cytotoxic T cell infiltration;
- b) polystyrene resin;
- c) LXXXXXXV (SEQ ID NO:1);
- d) inert molecular tag that can be decoded by gas-phase chromatography;
- e) foster antigen presenting cell;
- f) chromium releas by target cells;
- g) release upon exposure to an acid;
- h) *See above request for clarification**

In re: Nicolette
USSN: 10/041,977
Filed: January 9, 2002
Page 3

The Examiner has indicated that upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species that are written in dependent form or otherwise include all the limitations of an allowed generic claim.


Applicant looks forward to a favorable action on the merits.

SUMMARY

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

Date: 01/16/04
GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, MA 01701-9322


Deborah A. Dugan
Attorney for Applicant
Registration No. 37,315
Telephone: (508) 270-2598
Facsimile: (508) 872-5415